L-LOP/LOPP for the treatment of canine gastrointestinal/hepatosplenic lymphoma

• Published in: Frontiers in Veterinary Science
• Main Authors: Yu Ying Lai, Rodrigo dos Santos Horta, Angel Almendros, Patrick W. Y. Ha, Antonio Giuliano
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2024-05-01
• Subjects: canine; lymphoma; gastrointestinal; hepatosplenic; chemotherapy; LOP
• Online Access: https://www.frontiersin.org/articles/10.3389/fvets.2024.1373180/full

Canine gastrointestinal (GI) and hepatosplenic (HS) high-grade (large cell) lymphomas are uncommon forms of canine lymphomas, with a very poor response to chemotherapy and a very poor prognosis. Currently, there are no established effective chemotherapy protocols for canine GI/HS lymphomas. This case series aimed to retrospectively evaluate the efficacy of lomustine-based protocols L-LOP (L-asparaginase, lomustine, vincristine, and prednisolone) and L-LOPP (with the addition of procarbazine) for treatment of canine GI/HS lymphomas. Medical records of dogs with cytologically or histologically diagnosed lymphoma at CityU Veterinary Medical Centre from 2019 to 2022 were retrospectively reviewed. The L-LOP/LOPP treatment protocol was well tolerated with rare severe adverse events. Median progression-free survival for GI and HS lymphoma was 56 days (range, 10–274 days) and 57 days (range 8–135 days) respectively; while median survival time for GI and HS lymphoma was 93 days (range 10–325 days) and 210 days (range 8–240 days) respectively.